摘要
背景慢性阻塞性肺疾病急性加重期(AECOPD)患者病情危重、治疗难度较大,且死亡率高,因此寻找治疗AECOPD的有效方法非常重要。丙酸氟替卡松与特布他林治疗AECOPD的疗效确切,但二者对免疫功能及炎性反应的影响尚未完全明确。目的分析丙酸氟替卡松联合特布他林治疗AECOPD患者的临床疗效及其对免疫功能、炎性反应的影响。方法选取亳州市中医院肺病科2018年10月—2020年10月收治的AECOPD患者88例,根据治疗方法不同分为A组与B组,每组44例。在常规治疗基础上,A组患者予以特布他林治疗,B组患者予以丙酸氟替卡松联合特布他林治疗,两组患者均连续治疗7 d。比较两组患者治疗前后免疫功能指标〔免疫球蛋白(Ig)A、IgG、IgM〕、炎性指标〔白介素(IL)-6、IL-8及肿瘤坏死因子α(TNF-α)〕、肺功能指标〔第1秒用力呼气容积(FEV1)、用力肺活量(FVC)及第1秒用力呼气容积与用力肺活量的比值(FEV1/FVC)〕、慢性阻塞性肺疾病评估测试(CAT)评分及临床疗效、治疗期间不良反应发生情况。结果B组患者治疗后IgA、IgG及IgM高于A组,IL-6、IL-8及TNF-α低于A组(P<0.05)。B组患者治疗后FEV1、FVC大于A组,FEV1/FVC高于A组,CAT评分低于A组(P<0.05)。B组患者临床疗效优于A组(P<0.05);两组患者治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论丙酸氟替卡松联合特布他林治疗AECOPD的临床疗效确切,有助于增强患者免疫功能,减轻炎性反应,改善患者肺功能及生活质量,且安全性高。
Background Patients with acute exacerbation of chronic obstructive pulmonary disease(AECOPD)are critically ill,difficult to treat and have high mortality.Therefore,it is very important and necessary to explore the effective treatment of AECOPD.Fluticasone propionate and terbutaline are effective in the treatment of AECOPD,but their effects on immune function and inflammatory response are fully unclear.Objective To analyze the clinical efficacy of fluticasone propionate combined with terbutaline in the treatment of patients with AECOPD and its impact on immune function and inflammatory reaction.Methods From October 2018 to October 2020,88 patients with AECOPD in Department of Lung Diseases,Bozhou Hospital of Traditional Chinese Medicine were selected and divided into group A and group B,with 44 cases in each group.Group A was treated with terbutaline on the base of routine therapy,while group B was treated with fluticasone propionate combined with terbutaline on the base of routine therapy.Both groups were treated for 7 days.The immune function indexes〔immunoglobulin(Ig)A,IgG,IgM〕,inflammatory indexes〔Interleukin(IL)-6,IL-8,tumor necrosis factor alpha(TNF-α)〕,pulmonary function indexes〔forced expiratory volume in one second(FEV1),forced vital capacity(FVC),FEV1/FVC〕,COPD Assessment Test(CAT)score were compared between the two groups before and after treatment,and clinical efficacy,adverse reactions during treatment were recorded.Results After treatment,IgA,IgG and IgM in group B were higher than those in group A,while IL-6,IL-8 and TNF-αin group B were lower than those in group A(P<0.05).After treatment,FEV1 and FVC in group B were higher than those in group A,FEV1/FVC was higher than that in group A,CAT score was lower than that in group A(P<0.05).The clinical efficacy in group B was better than that in group A(P<0.05);there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion The clinical efficacy that fluticasone propionate combined with ter
作者
李芳
吴成明
程玉峰
LI Fang;WU Chengming;CHENG Yufeng(Department of Lung Diseases,Bozhou Hospital of Traditional Chinese Medicine,Bozhou 236800,China)
出处
《实用心脑肺血管病杂志》
2021年第3期91-95,共5页
Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease
基金
亳州市(2019年)第一批重点研发计划自筹经费项目(bzzc2019024)。
关键词
慢性阻塞性肺疾病
急性加重期
丙酸氟替卡松
特布他林
免疫功能
炎性反应
肺功能
生活质量
Chronic obstructive pulmonary disease
Acute exacerbation
Fluticasone propionate
Terbutaline
Immune function
Inflammatory response
Pulmonary function
Quality of life
